DK0697859T3 - Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH - Google Patents

Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH

Info

Publication number: DK0697859T3
Authority: DK; Denmark
Prior art keywords: nadph; stable; oral; nadp; therapeutic preparations
Prior art date: 1993-04-29

Application number

DK94914734.2T

Other languages

English (en)

Inventor

Joerg G D Birkmayer

Original Assignee

Birkmayer Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-29

Filing date

1994-03-25

Publication date

1997-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21995236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0697859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-03-25 Application filed by Birkmayer Pharmaceuticals Inc filed Critical Birkmayer Pharmaceuticals Inc

1997-12-29 Application granted granted Critical

1997-12-29 Publication of DK0697859T3 publication Critical patent/DK0697859T3/da

Links

229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title abstract 5
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 title abstract 4
230000001225 therapeutic effect Effects 0.000 title abstract 3
238000002360 preparation method Methods 0.000 title 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 abstract 2
239000006187 pill Substances 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000011253 protective coating Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK94914734.2T 1993-04-29 1994-03-25 Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH DK0697859T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/055,049 US5332727A (en)	1993-04-29	1993-04-29	Stable, ingestable and absorbable NADH and NADPH therapeutic compositions

Publications (1)

Publication Number	Publication Date
DK0697859T3 true DK0697859T3 (da)	1997-12-29

Family

ID=21995236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94914734.2T DK0697859T3 (da)	1993-04-29	1994-03-25	Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH

Country Status (16)

Country	Link
US (1)	US5332727A (da)
EP (1)	EP0697859B1 (da)
JP (1)	JP3683582B2 (da)
CN (1)	CN1072483C (da)
AT (1)	ATE153853T1 (da)
AU (1)	AU674583B2 (da)
BR (1)	BR9406514A (da)
CA (1)	CA2161641C (da)
DE (1)	DE69403656T2 (da)
DK (1)	DK0697859T3 (da)
ES (1)	ES2103587T3 (da)
GR (1)	GR3024561T3 (da)
IL (1)	IL109186A (da)
MX (1)	MX9402938A (da)
TW (1)	TW336895B (da)
WO (1)	WO1994025007A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2735293A1 (en) *	1995-01-17	1996-07-18	Menuco Corp.	Nadh and nadph therapeutic agents for dermal administration
US5712259A (en) *	1996-04-22	1998-01-27	Birkmayer Pharmaceuticals	NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) *	1996-05-08	1997-09-16	Birkmayer Pharmaceuticals	NADH and NADPH pharmaceuticals for treating hypertension
US6340474B1 (en)	1999-08-03	2002-01-22	Charles A. Mesko	Composition for potentiating a growth hormone and a method for preparation of said composition
IT1318565B1 (it) *	2000-06-09	2003-08-27	World Pharma Tech Ltd	Integratore alimentare proenergetico a base di nadh octocosanolo evitamina e.
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
AR034813A1 (es) *	2001-07-20	2004-03-17	Novartis Ag	Composiciones farmaceuticas y uso de las mismas
ITBO20020140A1 (it) *	2002-03-21	2003-09-22	Valpharma Sa	Formulazioni a base di nadh in forma di multiparticolato con rivestimento gastroresistente o a rilascio modificato
AT502435B1 (de) *	2002-11-19	2008-01-15	Oekopharm Forschungs Und Entwi	Pharmazeutische zusammensetzung umfassend ein wasserstoffübertragendes coenzym und chlorophyll
JPWO2004050099A1 (ja) *	2002-12-03	2006-03-30	協和醗酵工業株式会社	還元型ニコチンアミドアデニンジヌクレオチドまたは還元型ニコチンアミドアデニンジヌクレオチドホスフェイトの安定化方法
US20040126751A1 (en) *	2002-12-27	2004-07-01	Birkmayer Jorg G.D.	Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US20050226923A1 (en) *	2004-04-07	2005-10-13	Gassert Chad M	Venlafaxine compositions in the form of microtablets
BRPI0509385A (pt) *	2004-04-08	2007-09-18	Wyeth Corp	composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto
PA8629301A1 (es) *	2004-04-08	2006-10-13	Wyeth Corp	Formulaciones de acetato de bezedoxifeno
WO2006073162A1 (ja) *	2005-01-07	2006-07-13	Kyowa Hakko Kogyo Co., Ltd.	Nadhもしくはnadphまたはその塩の保存安定性向上方法
JPWO2006106805A1 (ja) *	2005-03-30	2008-09-11	協和醗酵工業株式会社	物質の保存安定性向上方法
ITMI20060629A1 (it) *	2006-03-31	2007-10-01	Daniele Giovannone	Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
ITMI20071374A1 (it)	2007-07-10	2009-01-11	Gnosis Spa	Sali stabili di s-adenosilmetionina e processo per il loro ottenimento.
US20100200237A1 (en) *	2009-02-12	2010-08-12	Colgate Sam O	Methods for controlling temperatures in the environments of gas and oil wells
US20100236784A1 (en) *	2009-03-20	2010-09-23	Horton Robert L	Miscible stimulation and flooding of petroliferous formations utilizing viscosified oil-based fluids
US20100252259A1 (en) *	2009-04-01	2010-10-07	Horton Robert L	Oil-based hydraulic fracturing fluids and breakers and methods of preparation and use
US20100263867A1 (en) *	2009-04-21	2010-10-21	Horton Amy C	Utilizing electromagnetic radiation to activate filtercake breakers downhole
DE102012104451A1 (de) *	2012-05-23	2013-11-28	Jürgen Ruhlmann	Komposition zur Behandlung einer Störung des circadianen Rhythmus
WO2015156922A1 (en) *	2014-04-08	2015-10-15	Dow Global Technologies Llc	Dispersion comprising an esterified cellulose ether
RU2545920C1 (ru) *	2014-04-23	2015-04-10	Аллан Герович Бениашвили	Композиция nadh, обладающая антиоксидантными свойствами
EP2944312B1 (de)	2014-05-16	2022-01-26	TP Tumapharma Ltd	Kombinationspräparat, umfassend glucosamin und chondroitinsulfat
CN104840479A (zh) *	2015-02-17	2015-08-19	苏州人本药业有限公司	Nadph在制备治疗心脏疾病药物中的应用
CN104758307A (zh) *	2015-03-16	2015-07-08	邦泰生物工程(深圳)有限公司	Nadh和nmn在制备帕金森病药物或保健品的应用
WO2019028877A1 (zh) *	2017-08-11	2019-02-14	邦泰生物工程(深圳)有限公司	一种含有nadh和nadph的组合物及其应用
CN109893510A (zh) *	2019-02-28	2019-06-18	合肥康诺药物开发有限公司	一种辅酶i肠溶片及其制备方法
BR102020013862A2 (pt) *	2020-07-07	2022-01-18	Edson Luiz Peracchi	Implante subcutâneo reabsorvível de longa duração com liberação sustentada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da doença de parkinson
DE202022000567U1 (de)	2022-03-06	2022-03-16	Penta Phi Eg	Liposomale Formulierung
CN119157897A (zh) *	2023-10-12	2024-12-20	苏州人本药业有限公司	Nadph在制备治疗重性抑郁症、双向抑郁症、脑卒中后抑郁症或神经炎症药物的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1930059C3 (de) *	1969-06-13	1975-11-13	Boehringer Mannheim Gmbh	Stabilisiertes Nicotinamid-adenindinucleotid oder bzw. und Nicotinamld-adenin-dinucleotidphosphat
GB1359643A (en) *	1970-09-28	1974-07-10	Controlled Medications	Controlled release medicament
CA1187388A (en) *	1978-09-20	1985-05-21	American Monitor Corporation	Stabilization of working reagent solutions containing nadh, nadph, and/or enzymes, and the use of such stabilized reagents in enzymes or substrate assays
JPS5748908A (en) *	1980-09-08	1982-03-20	Kyorin Pharmaceut Co Ltd	Prolonged release type nicomol pharmaceutical
DE3126703A1 (de) *	1981-07-07	1983-01-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Bromhexin-retardform und verfahren zu ihrer herstellung
JPS59227817A (ja) *	1983-06-07	1984-12-21	Toyo Jozo Co Ltd	持続性経口用ブレデニン製剤
JPS6144811A (ja) *	1984-08-10	1986-03-04	Ss Pharmaceut Co Ltd	徐放性ジクロフエナクナトリウム製剤
CA1336169C (en) *	1988-03-01	1995-07-04	Walther Birkmayer	Agent for treatment of parkinson's disease
AT397201B (de) *	1988-06-03	1994-02-25	Birkmayer Joerg Ddr	Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
JPH01308231A (ja) *	1988-06-03	1989-12-12	Takeda Chem Ind Ltd	安定化された医薬組成物および製造法
US5135757A (en) *	1988-09-19	1992-08-04	Edward Mendell Co., Inc.	Compressible sustained release solid dosage forms

1993
- 1993-04-29 US US08/055,049 patent/US5332727A/en not_active Expired - Lifetime
1994
- 1994-03-25 EP EP94914734A patent/EP0697859B1/en not_active Expired - Lifetime
- 1994-03-25 DK DK94914734.2T patent/DK0697859T3/da active
- 1994-03-25 AU AU66980/94A patent/AU674583B2/en not_active Ceased
- 1994-03-25 WO PCT/US1994/003290 patent/WO1994025007A1/en not_active Ceased
- 1994-03-25 AT AT94914734T patent/ATE153853T1/de active
- 1994-03-25 DE DE69403656T patent/DE69403656T2/de not_active Expired - Lifetime
- 1994-03-25 JP JP52425894A patent/JP3683582B2/ja not_active Expired - Lifetime
- 1994-03-25 BR BR9406514A patent/BR9406514A/pt not_active Application Discontinuation
- 1994-03-25 CN CN94191939A patent/CN1072483C/zh not_active Expired - Fee Related
- 1994-03-25 ES ES94914734T patent/ES2103587T3/es not_active Expired - Lifetime
- 1994-03-25 CA CA002161641A patent/CA2161641C/en not_active Expired - Lifetime
- 1994-03-31 IL IL10918694A patent/IL109186A/xx not_active IP Right Cessation
- 1994-04-22 MX MX9402938A patent/MX9402938A/es not_active IP Right Cessation
- 1994-04-29 TW TW083103881A patent/TW336895B/zh not_active IP Right Cessation
1997
- 1997-08-28 GR GR970402200T patent/GR3024561T3/el unknown

Also Published As

Publication number	Publication date
GR3024561T3 (en)	1997-12-31
JP3683582B2 (ja)	2005-08-17
TW336895B (en)	1998-07-21
ES2103587T3 (es)	1997-09-16
EP0697859A1 (en)	1996-02-28
IL109186A0 (en)	1994-06-24
MX9402938A (es)	1995-01-31
AU674583B2 (en)	1997-01-02
IL109186A (en)	2000-01-31
US5332727A (en)	1994-07-26
ATE153853T1 (de)	1997-06-15
CN1121688A (zh)	1996-05-01
CA2161641A1 (en)	1994-11-10
WO1994025007A1 (en)	1994-11-10
BR9406514A (pt)	1996-01-09
DE69403656T2 (de)	1997-10-16
CN1072483C (zh)	2001-10-10
DE69403656D1 (de)	1997-07-10
AU6698094A (en)	1994-11-21
JPH08512021A (ja)	1996-12-17
CA2161641C (en)	1999-06-15
EP0697859B1 (en)	1997-06-04
EP0697859A4 (en)	1996-06-26

Publication	Publication Date	Title
ATE153853T1 (de)	1997-06-15	Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
DE69701532D1 (de)	2000-04-27	Orale zusammensetzung gegen zahnbelag
LT97200A (en)	1998-09-25	Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
DK0841904T3 (da)	2003-05-26	Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
EP2261200A3 (en)	2010-12-29	Modified forms of pharmacacologically active agents and uses therefor
DE3586959D1 (de)	1993-02-18	Desinfektionsverfahren sowie zusammensetzung dafuer.
ATE324872T1 (de)	2006-06-15	Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
AU7702291A (en)	1991-11-28	Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
NZ314442A (en)	1999-06-29	Extended release formulation comprising venlafaxine hydrochloride, film coating composition
IS1812B (is)	2002-05-15	Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
MXPA97002401A (es)	2004-08-20	Agente antiinflamatorio para uso externo.
PT615754E (pt)	2002-11-29	Formas solidas de administracao oral de libertacao controlada flupertina
NO954878L (no)	1996-06-03	Pyrrolderivater
IS4553A (is)	1997-08-27	Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
MY121864A (en)	2006-02-28	Condensed thienopyrimidines with phosphodiesterase-v inhibiting action.
AU5686196A (en)	1996-10-23	Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses
TR200001102T2 (tr)	2000-08-21	İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
EP0345248A3 (de)	1991-03-06	Verwendung des Enzym-Cofaktors NADPH zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung
DE58902899D1 (de)	1993-01-14	2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
NO922842D0 (no)	1992-07-17	Benzotiazolderivater, fremgangsmaate for deres fremstilling og deres anvendelse som terapeutika
AU7865791A (en)	1992-01-07	Anti-actinic agent
NO993435L (no)	1999-07-12	Transdermalt acetylsalicylsyre inneholdende terapeutisk system med forsterket resorpsjon
AU7028798A (en)	1998-09-22	Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
NO895049L (no)	1990-06-18	Fremgangsmaate for tilvirkning av polyorganosiloksan og ensammensetning som er utherdbar med straaling.
DK1062954T3 (da)	2007-09-10	Anvendelse af itakonsyre til regulering af det glykotiske stofskifte